Biogen announced that the European Medicines Agency (EMA) has accepted the marketing authorization application seeking approval of antisense drug, tofersen in patients with amyotrophic lateral sclerosis (“ALS”) with superoxide dismutase 1 (“SOD1”) mutation.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,